Please login to the form below

Not currently logged in
Email:
Password:

GSK refocuses MS drug development

GlaxoSmithKline has decided to refocus development efforts for MS drug ofatumumab on an injectable rather than an intravenous formulation

GlaxoSmithKline (GSK) has decided to refocus development efforts for ofatumumab, a human monoclonal antibody being tested for multiple sclerosis (MS) and other autoimmune indications, on an injectable rather than an intravenous formulation. This is in order to maximise convenience and tolerability for patients.

GSK and the Danish firm Genmab restructured their collaborative agreement for the drug this summer in order to give GSK development responsibility for autoimmune indications. Following that change, GSK reviewed the development strategy and determined that it should focus on the subcutaneous delivery of ofatumumab in autoimmune indications.

GSK said it will stop development of the intravenous version in autoimmune disease in spite of clinical data showing efficacy for the formulation in MS and rheumatoid arthritis.

Earlier this month, the companies released positive phase I/II study data for ofatumumab in MS. GSK plans to begin a phase IIb dose ranging study in MS using the subcutaneous formulation next year. Further development of the subcutaneous drug in rheumatoid arthritis is under review, the company said.

The two companies continue to be jointly responsible for the development of an intravenous formulation of the product for oncology indications. A phase II trial of ofatumumab in combination with bendamustine in patients with indolent B-cell non-Hodgkin's lymphoma was initiated in early September.

16th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics